Fate Therapeutics (FATE) Invested Capital (2016 - 2025)
Historic Invested Capital for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $234.1 million.
- Fate Therapeutics' Invested Capital fell 3539.91% to $234.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.1 million, marking a year-over-year decrease of 3539.91%. This contributed to the annual value of $318.7 million for FY2024, which is 1348.77% down from last year.
- Fate Therapeutics' Invested Capital amounted to $234.1 million in Q3 2025, which was down 3539.91% from $261.4 million recorded in Q2 2025.
- In the past 5 years, Fate Therapeutics' Invested Capital ranged from a high of $790.1 million in Q1 2021 and a low of $234.1 million during Q3 2025
- Over the past 5 years, Fate Therapeutics' median Invested Capital value was $437.8 million (recorded in 2023), while the average stood at $481.1 million.
- In the last 5 years, Fate Therapeutics' Invested Capital soared by 26036.59% in 2021 and then crashed by 3539.91% in 2025.
- Over the past 5 years, Fate Therapeutics' Invested Capital (Quarter) stood at $678.8 million in 2021, then fell by 28.71% to $483.9 million in 2022, then dropped by 23.87% to $368.4 million in 2023, then fell by 13.49% to $318.7 million in 2024, then decreased by 26.56% to $234.1 million in 2025.
- Its Invested Capital stands at $234.1 million for Q3 2025, versus $261.4 million for Q2 2025 and $288.4 million for Q1 2025.